Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells

Transfusion

Volumn 46, Issue 7, 2006, Pages 1199-1209

  Janowska Wieczorek, Anna ^a   Marquez Curtis, Leah A ^b   Wysoczynski, Marcin ^b   Ratajczak, Mariusz Z ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; FIBRINOGEN RECEPTOR; GELATINASE B; INTEGRIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; STROMAL CELL DERIVED FACTOR 1;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CHEMOTAXIS; CONTROLLED STUDY; ENDOSOME; ENZYME PHOSPHORYLATION; FIBROBLAST; HUMAN; HUMAN CELL; METASTASIS; PLATELET DERIVED MICROVESICLE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THROMBOCYTE; THROMBOCYTE TRANSFUSION;

BLOOD PLATELETS; BREAST NEOPLASMS; CELL ADHESION; CELL COMMUNICATION; CELL LINE, TUMOR; CHEMOTAXIS; COCULTURE TECHNIQUES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHORYLATION; PLATELET ACTIVATION; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 33746555498     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00871.x     Document Type: Article

References (49)

1. Honn KV, Tang DG, Crissman JD. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev 1992;11:325-51.
2. Nash GF, Turner LF, Scully MF, Kakkar AK. Platelets and cancer. Lancet Oncol 2002;3:425-30.
3. Gupta GP, Massague J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest 2004;114:1691-3.
4. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol 1999;30:111-42.
5. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and α-granules. Blood 1999;94:3791-9.
6. Rinder HM, Snyder EL. Activation of platelet concentrate during preparation and storage. Blood Cells 1992;18:445-60.
7. Hagberg IA, Akkok CA, Lyberg T, Kjeldsen-Kragh J. Apheresis-induced platelet activation: comparison of three types of cell separators. Transfusion 2000;40:182-92.
8. Gemmell CH, Ramirez SM, Yeo EL, Sefton MV. Platelet activation in whole blood by artificial surfaces: identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events. J Lab Clin Med 1995;125:276-87.
9. Baj-Krzyworzeka M, Majka M, Pratico D, et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 2002;30:450-9.
10. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005;113:752-60.
11. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
12. Murphy PM. Chemokines and the molecular basis of cancer metastasis. N Engl J Med 2001;345:833-5.
13. Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004;64:8604-12.
14. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-13.
15. Stamenkovic I. Extracellular matrix remodeling: the role of matrix metalloproteinases. J Pathol 2003;200:448-64.
16. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
17. Yana I, Seiki M. MT-MMPs play pivotal roles in cancer dissemination. Clin Exp Metastasis 2002;19:209-15.
18. Zucker S, Pei D, Cao J, et al. Membrane type-matrix metalloproteinases (MT-MMP). In: Zucker S, Chen WT, editors. Current topics in developmental biology: cell surface proteases. New York: Academic Press; 2003. p. 1-74.
19. Sounni NE, Janssen M, Foidart JM, Noel A. Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol 2003;22:55-61.
20. Somerville RP, Oblander SA, Apte SS. Matrix metalloproteinases: old dogs with new tricks. Genome Biol 2003;4: 1-11.
21. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998;83:1153-62.
22. Rha SY, Kim JH, Roh JK, et al. Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. Breast Cancer Res Treat 1997; 43:175-81.
23. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994;370:61-5.
24. Singer CF, Kronsteiner N, Marton E, et al. MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res Treat 2002;72:69-77.
25. Mayani H, Guilbert LJ, Clark SC, et al. Composition and functional integrity of the in vitro hemopoietic microenvironment in acute myelogenous leukemia: effect of macrophage colony-stimulating factor. Exp Hematol 1992; 20:1077-84.
26. Janowska-Wieczorek A, Marquez LA, Nabholtz JM, et al. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34+ cells and their transmigration through reconstituted basement membrane. Blood 1999;93:3379-90.
27. Marquez-Curtis LA, Dobrowsky A, Montano J, et al. Matrix metalloproteinase and tissue inhibitor of metalloproteinase secretion by hematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures. Br J Haematol 2001;115:595-604.
28. Saad S, Gottlieb DJ, Bradstock KF, Overall CM, Bendall LJ. Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Res 2002;62:283-9.
29. 3 integrins in tumor growth, angiogenesis and metastasis. Cancer Res 2002;62:2824-33.
30. Camerer E, Qazi AA, Duong DN, et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004;104:397-401.
31. Saad S, Bendall LJ, James A, Gottlieb DJ, Bradstock KF. Induction of matrix metalloproteinases MMP-1 and MMP-2 by co-culture of breast cancer cells and bone marrow fibroblasts. Breast Cancer Res Treat 2000;63:105-15.
32. Rozmyslowicz T, Majka M, Kijowski J, et al. Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. AIDS 2003;17:33-42.
33. Wysoczynski M, Reca R, Ratajczak J, et al. Incorporation of CXCR4 into membrane lipid rafts primes homing-related responses of hematopoietic stem/progenitor cells to an SDF-1 gradient. Blood 2005;105:40-8.
34. Epstein RJ. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 2004;4:901-9.
35. Bachmeier BE, Nerlich AG, Lichtinghagen R, Sommerhoff CP. Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity. Anticancer Res 2001;21: 3821-8.
36. Lindenmeyer F, Legrand Y, Menashi S. Upregulation of MMP-9 expression in MDA-MB231 tumor cells by platelet granular membrane. FEBS Lett 1997;418:19-22.
37. Kajita M, Itoh Y, Chiba T, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001;153:893-904.
38. Endo K, Takino T, Miyamori H, et al. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 2003;278:40764-70.
39. Yamakawa S, Asai T, Uchida T, et al. (-)-Epigallocatechin gallate inhibits membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor angiogenesis. Cancer Lett 2004; 210:47-55.
40. Langlois S, Gingras D, Beliveau R. Membrane type-1 matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation. Blood 2004;103:3020-8.
41. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996;149:273-82.
42. Wang TN, Albo D, Tuszynski GP. Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production. Surgery 2002;132: 220-5.
43. Kobayashi T, Hattori S, Shinkai H. Matrix metalloproteinases-2 and -9 are secreted from human fibroblasts. Acta Derm Venereol 2003;83:105-7.
44. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21:968-75.
45. Nabholtz JM, Smylie M, Mackey J, et al. Docetaxel/doxorubicin/ cyclophosphamide in the treatment of metastatic breast cancer. Oncology 1997;11:25-7.
46. Forlow SB, McEver RP, Nollert MU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood 2000;95:1317-23.
47. Krailadsiri P, Seghatchian J, Williamson LM. Platelet storage lesion of WBC-reduced, pooled, buffy coat-derived platelet concentrates prepared in three in-process filter/storage bag combinations. Transfusion 2001;41:243-50.
48. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
49. Muller V, Pantel K. BM micrometastases and circulating tumor cells in breast cancer patients: where have we been, where are we now and where does the future lie? Cytotherapy 2005;7:478-82.